Zurcher Kantonalbank Zurich Cantonalbank lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 198,891 shares of the medical research company’s stock after selling 36,955 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Thermo Fisher Scientific were worth $37,630,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the company. Proficio Capital Partners LLC raised its stake in Thermo Fisher Scientific by 71.5% during the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after acquiring an additional 253 shares during the period. Shine Investment Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $113,000. Chicago Partners Investment Group LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $108,000. Ropes Wealth Advisors LLC raised its stake in Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after acquiring an additional 97 shares during the period. Finally, Atlantic Trust LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $138,000. Hedge funds and other institutional investors own 86.16% of the company’s stock.
In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the transaction, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.49% of the company’s stock.
Shares of Thermo Fisher Scientific Inc. (TMO) traded up $2.33 on Friday, reaching $187.96. 2,429,212 shares of the company’s stock were exchanged, compared to its average volume of 1,666,042. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific Inc. has a twelve month low of $139.88 and a twelve month high of $201.20. The stock has a market cap of $75,371.02, a price-to-earnings ratio of 20.65, a P/E/G ratio of 1.72 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same period last year, the firm posted $2.03 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% compared to the same quarter last year. equities research analysts expect that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.
A number of research firms have commented on TMO. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Barclays reaffirmed an “overweight” rating and set a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Jefferies Group reaffirmed a “hold” rating and set a $195.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $220.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus price target of $205.21.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/10/zurcher-kantonalbank-zurich-cantonalbank-sells-36955-shares-of-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.